Nanobac Competitors

NNBP Stock  USD 0.0001  0.00  0.00%   
Analyzing Nanobac Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nanobac Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Nanobac Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nanobac Pharmaceuticals competition on your existing holdings.
At this time, Nanobac Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 01/11/2026, Return On Equity is likely to grow to 2.63, though Return On Tangible Assets are likely to grow to (92.96). At this time, Nanobac Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 01/11/2026, Intangible Assets is likely to grow to about 4.2 M, while Net Tangible Assets are likely to drop (9 M).
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details
Naive
Forecast
LowNextHigh
0.00010.00010.0001
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00010.00010.0001
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Nanobac Pharmaceuticals. Your research has to be compared to or analyzed against Nanobac Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Nanobac Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Nanobac Pharmaceuticals.

Nanobac Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nanobac Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nanobac and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nanobac Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

NSPDFMRPI
ACBMONBI
CEOSLADX
CEOSMLPH
ISOLFMLPH
ISOLFONBI
  

High negative correlations

ONBILADX
CEOSONBI
ACBMLADX
CEOSACBM
ISOLFLADX
ISOLFCEOS

Risk-Adjusted Indicators

There is a big difference between Nanobac Stock performing well and Nanobac Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nanobac Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
LADX  19.93  4.66  0.07 (19.13) 21.63 
 53.85 
 491.67 
MLPH  6.63  2.63  0.00 (1.69) 0.00 
 0.00 
 193.33 
MRPI  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
ONBI  4.48  2.45  0.00 (1.00) 0.00 
 0.00 
 150.00 
ACBM  91.66  50.89  0.00 (0.90) 0.00 
 0.00 
 3,071 
OWCP  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
RBII  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
CEOS  12.31  1.34  0.06  18.51  15.61 
 28.21 
 100.91 
NSPDF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
ISOLF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 

Cross Equities Net Income Analysis

Compare Nanobac Pharmaceuticals and related stocks such as LadRx, Molecular Pharmacology, and Mera Pharmaceuticals Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026

Nanobac Pharmaceuticals and related stocks such as LadRx, Molecular Pharmacology, and Mera Pharmaceuticals Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Nanobac Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Nanobac Pharmaceuticals Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Nanobac Pharmaceuticals Competitive Analysis

The better you understand Nanobac Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nanobac Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nanobac Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NNBP LADX MLPH MRPI ONBI ACBM CEOS NSPDF ISOLF
 0.00 
 0.0001 
Nanobac
 0.00 
 0.01 
LadRx
 0.00 
 0.0004 
Molecular
 0.00 
 0.0001 
Mera
 0.00 
 0.0005 
ONE
 0.00 
 0.02 
ACRO
 3.13 
 0 
CeCors
 0.00 
 0.04 
Naturally
 0.00 
 0.0001 
Isodiol
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Z Score
Return On Asset
Book Value Per Share
Number Of Shares Shorted
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Daily Balance Of Power
Day Typical Price
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Nanobac Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Nanobac Pharmaceuticals Competition

Nanobac Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nanobac Pharmaceuticals in relation to its competition. Nanobac Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nanobac Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nanobac Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nanobac Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nanobac Pharmaceuticals position

In addition to having Nanobac Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hedge Favorites Thematic Idea Now

Hedge Favorites
Hedge Favorites Theme
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.